NxStage Announces CE Mark Approval for New High Flow Capabilities with System
Latest Pipeline Advancement Expands Therapeutic Flexibility of System One
LAWRENCE, Mass., Feb. 21, 2013
LAWRENCE, Mass., Feb. 21, 2013 /PRNewswire/ --NxStage® Medical, Inc. (Nasdaq:
NXTM), a leading manufacturer of innovative dialysis products, today announced
CE Mark approval for new high flow capabilities with the NxStage System One™.
With this approval, the Company expects to bring this advancement to customers
in countries that recognize the CE Mark approval process later this year.
(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )
The new high flow capabilities for the System One will enable dialysate flow
rates which allow nephrologists expanded possibilities to adjust the duration
and frequency of patient prescriptions with greater flexibility than they have
"Our new high flow capabilities advance the therapeutic flexibility of the
System One as well as NxStage's leadership in home therapies," said Jeffrey
Burbank, Chief Executive Officer, NxStage Medical, Inc. "By providing expanded
therapy options, high flow enables NxStage therapy to be even better tailored
to the clinical and lifestyle needs of a broader range of patients."
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis
system cleared for home use by theU.S. Food & Drug Administration(FDA). Its
simplicity and revolutionary size (just over a foot tall) provide convenient
use in patients' homes and give patients the freedom to travel with their
therapy.Unlike conventional hemodialysis systems, the System One requires no
special infrastructure to operate. Under the guidance of their physician,
patients can use the NxStage System One, with their trained partners, where,
how and when it best meets their needs, at home or on the road.
About NxStage Medical Inc.
NxStage is a medical device company, headquartered in Lawrence, MA, USA, which
develops, manufactures, and markets innovative systems for the treatment of
end-stage renal disease (ESRD), and acute kidney failure. The System One home
hemodialysis device developed by NxStage is the only FDA approved portable
hemodialysis machine cleared for home use. For more information on NxStage, or
NxStage products, visit, http://www.nxstage.com.
This release contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements contained in
this release that are not clearly historical in nature are forward-looking,
and the words "anticipate," "believe," "expect," "estimate," "plan," and
similar expressions are generally intended to identify forward-looking
statements. Actual results may differ materially from those indicated by these
forward-looking statements as a result of various important factors including
those that are discussed in NxStage's filings with the Securities and Exchange
Commission, including the Quarterly Report on Form 10-Q for the quarter ended
September 30, 2012. NxStage is under no obligation to (and expressly disclaims
any such obligation to) update or alter its forward-looking statements,
whether as a result of new information, future events or otherwise.
CONTACT: NxStage Medical, Inc., email@example.com
SOURCE NxStage Medical, Inc.
Contact: Kristen Sheppard, +1-978-332-5923
Press spacebar to pause and continue. Press esc to stop.